Targeted therapies inhibit PCa bone metastasis

San Francisco-Prostate cancer bone metastases appear to react favorablyto treatment with a new bisphosphonate and the tyrosine-kinase inhibitorsPKI-166 and STI-571, according to studies presented at the American Associationfor Cancer Research annual meeting here.

Related Videos

Related Content

Advertisement

May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke

The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.

April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

April 5th 2025

Vaginal prolapse repair and sling surgery significantly reduce UUI

Christina M. Mezes, DO Catherine A. Matthews, MD

"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.

April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.

March 28th 2025

FDA grants marketing authorization to at-home diagnostic test for STIs

Hannah Clarke

The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.

March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.

Related Content

Advertisement

May 16th 2025

Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

Melissa Kaufman, MD, PhD, FACS Hannah Clarke

The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.

April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD

Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.

April 5th 2025

Vaginal prolapse repair and sling surgery significantly reduce UUI

Christina M. Mezes, DO Catherine A. Matthews, MD

"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.

April 28th 2025

Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

Melissa Kaufman, MD, PhD, FACS

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.

March 28th 2025

FDA grants marketing authorization to at-home diagnostic test for STIs

Hannah Clarke

The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.

March 25th 2025

Expert discusses unique mechanism of action of UTI treatment gepotidacin

Ryan Haumschild, PharmD, MS, MBA, CPEL

"I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.